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Abstract Since its first isolation in 1983, the human immunodeficiency virus (HIV) has infected over 77 million
 people and only one patient from whom the virus was completely removed from the body was docu-
mented. A recent second case was reported that remains to be confirmed. Antiretroviral therapy (ART) manages 
to control blood viral replication and, consequently, to restore −at least partially− the functions of the immune 
system with a notable reduction of the morbidity and mortality associated with HIV infection. However, given 
the difficulty in eliminating the virus from the body, treatment has to be given for life. This long-term exposure 
to antiretroviral drugs implies the risk of generating intolerance, toxic effects, gaps in adherence and selection 
of resistance mutations. Another limitation is the high cost of treating 37 million persons living with HIV, most of 
whom are living in resource-limited countries and relying on international aid initiatives. Having these challenges 
in mind, there is general agreement that new approaches for preventing and treating HIV infection are needed 
to control the epidemic, while efforts on vaccine development continue. In this regard, new generation broadly 
neutralising monoclonal antibodies (bnMAbs) against the HIV envelope protein can prevent virus acquisition, 
reduce viremia, enhance immunity, and induce the killing of infected cells in animal models of HIV infection. 
Most importantly, some clinical trials have shown that bnMAbs could effectively decrease viremia and delay viral 
rebound in people chronically infected with HIV.
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Resumen Nuevas estrategias para el control y la prevención de la infección por HIV. Desde su primer
 aislamiento en 1983, el virus de la inmunodeficiencia humana (HIV) ha infectado a más de 77 
millones de personas y solo se ha documentado un caso en el cual el virus fue removido completamente del 
organismo; aún resta confirmar un segundo caso informado recientemente. El tratamiento antirretroviral logra 
controlar la replicación viral en el plasma y en consecuencia recuperar (al menos parcialmente) la actividad del 
sistema inmune, con una notable reducción de la morbilidad y la mortalidad asociadas a la infección por HIV. 
Sin embargo, ante la dificultad para eliminar completamente el virus del organismo, es necesario continuar el 
tratamiento de por vida. Esto implica la exposición a largo plazo a drogas antirretrovirales con riesgo de generar 
intolerancia, efectos tóxicos, brechas en la adherencia y selección de mutantes resistentes. Otro aspecto a con-
siderar es la carga económica que implica tratar a 37 millones de personas infectadas con HIV, la mayoría de 
ellas en países que solo pueden afrontar esos costos con ayuda internacional. Por ello, hasta tanto se disponga 
de una vacuna capaz de prevenir la infección de todas las formas circulantes del HIV, es necesario desarrollar 
nuevas herramientas terapéuticas capaces de complementar y potenciar los efectos del tratamiento antirretrovi-
ral. Diversos ensayos preclínicos sugieren que la administración pasiva de anticuerpos monoclonales dirigidos 
contra la glicoproteína de envoltura viral podría prevenir la infección, reducir la carga viral, estimular la respuesta 
inmune y favorecer la eliminación de células infectadas con HIV.
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tratamiento y profilaxis de HIV
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The human immunodeficiency virus (HIV) targets 
CD4+ T-cells impairing irreversibly the immune system. 
Acquired immunodeficiency syndrome (AIDS) refers to 
the final stage of HIV infection, which is characterized 
by a compromised immune state (CD4+ T-cells counts 
< 200/ml) and the eventual presence of multiple concur-
rent opportunistic infections.  
In order to control the HIV epidemic it is necessary to 
strengthen prevention programs targeting populations at 
high risk of acquiring infections (i.e., men who has sex 
with men, transgender people and sex workers). The 
idea of combined prevention measures includes sex ed-
ucation, promoting safe sex practices including the use 
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and distribution of condoms, circumcision, treatment of 
other sexually transmitted infections, and pre-exposure 
prophylaxis (PrEP). In countries where the number of 
intravenous drug users is high, opioid substitution thera-
pies and safe injection sites should be provided in order 
to reduce HIV transmission. 
Heath care providers should give advice regarding 
the benefits of early HIV testing, counselling and therapy 
initiation. It has been demonstrated that HIV-infected 
people under antiretroviral therapy (ART) who are virally 
suppressed (i.e. < 200 HIV copies per blood millilitre for 
< 6 months) do not transmit the virus sexually and can 
even prevent transmission through syringe sharing and 
from mother-to-child during pregnancy. This underlies the 
concept of “treatment as prevention” or “U = U” (undetect-
able = untransmissable). It should also be considered that 
social stigma and discrimination increase vulnerability and 
hinder prevention, treatment and care of people living with 
HIV or at risk of acquiring it.
Antiretroviral drugs to control and prevent HIV
In the absence of an effective vaccine, ART constitutes 
the most effective preventive and therapeutic strategy 
against HIV. Antiretroviral drugs interact with various 
viral components, interfering with their biological cycle. 
With adequate adherence to treatment, these drugs 
suppress viral replication, reaching undetectable 
plasma viral load levels both in plasma and genital 
secretions. At an individual level, this translates into an 
immunological and clinical improvement, as well as a 
reduction in mortality due to secondary diseases, such 
as opportunistic infections and cancer1. Further, the viral 
load suppression eliminates the risk of horizontal and 
vertical transmission of HIV2. These principles constitute 
the fundamental basis of the strategy called “treatment 
as prevention”. Therefore, we must emphasize the im-
portance of initiating treatment immediately, once the 
patient is ready3. 
Thanks to the recent availability of a wide spectrum of 
drugs that achieve virological control, the objectives are 
currently focused on simplifying therapeutic regimens. To 
this end, the trend is towards regimens including only two 
drugs with long half-life that allow weekly, monthly, or even 
semi-annual dosing. Dual therapy protocols improved safe-
ty, tolerability, and treatment adherence with lower risk of 
default4-7. In addition, this strategy reduces treatment costs, 
both for people without prior treatment (naïve) and for those 
on a triple therapy regimen with undetectable viral load levels. 
Also for aging persons living with HIV, dual therapy presents 
an effective alternative to prevent the appearance of side 
effects associated with prolonged antiretroviral treatment. 
Although the preferred regimens are still the combination 
of three agents active against HIV, international and local 
guidelines list dual therapy as an alternative8, 9. 
Another obstacle to HIV treatment is the emergence of 
HIV resistance to antiretrovirals. New therapeutic approach-
es are needed for treating patients who no longer have 
effective drug combinations available. One is ibalizumab 
(TMB-355), a monoclonal antibody that acts on the CD4 
receptor of helper T-lymphocytes10, instead of directly on 
the virus (as explained in the following section). Recent 
studies have shown a reduction in the viral load of patients 
infected with multi-resistant HIV, stemming from the use of 
ibalizumab as part of ART. Another novel aspect of this drug 
is that it has been approved for injectable dosing every two 
weeks. In this way, long-acting antiretrovirals gain further 
relevance. The main drawback of this compound is its 
exorbitant cost.
The possibility of administering monthly or bi-
monthly treatment would be an option for people 
with adherence problems. Along this line of re-
search, clinical studies are being carried out to 
allow approval of long-acting injectable drugs, both 
for treatment and use in pre-exposure prophylaxis 
(PrEP)11, 12. The ATLAS study (NCT02951052) has 
demonstrated non-inferiority of an injectable regimen 
of two prolonged-release drugs (cabotegravir and 
rilpivirine) every 4 weeks compared to maintenance 
of the current ART regimen. Along this same line, 
the FLAIR study (NCT03299049) uses the same drug 
regimen, but with 8-week intervals, this time in naïve 
patients following 24 weeks of oral induction. With 
a similar model, new studies are being developed 
(NCT02720094 and NCT03164564) directed at high 
risk populations, which incorporate this type of dosing 
as PrEP in order to optimize adherence.
The efficacy of PrEP using antiretroviral agents (ten-
ofovir/ emtricitabine, taken orally) has been established 
in clinical trials involving transgender women, men who 
have sex with men, heterosexual populations, and intra-
venous drug users. These results have generated the 
formal recommendation of PrEP by multiple agencies 
and scientific entities13. It is important to emphasize that 
the strategy of selection of potential candidates for these 
studies must include people in whom HIV infection has 
been ruled out and who are at marked risk of acquiring 
it. With the success of PrEP closely related to medica-
tion adherence, health services providing PrEP must 
analyse each case punctually, in addition to providing 
access to HIV testing and other sexually transmitted 
infections, including hepatitis B, and prescribing the 
corresponding vaccines when appropriate. The global 
increase in ART coverage has reduced the number of 
AIDS-associated deaths, mostly due to the reduction 
in new infections. However, several obstacles must still 
be overcome.
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Neutralizing antibody therapy and 
prophylaxis
The rapid establishment of a latent reservoir in its provirus 
form, the high mutation and replication rate, and the direct 
impairment of key immune components are some features 
that allow HIV to effectively evade the immune response. 
However, most HIV+ patients develop a strong and specif-
ic immune response against HIV. Moreover, a small num-
ber of HIV+ patients (1%) develop neutralizing antibodies 
accounting for a remarkable neutralization breadth (able of 
neutralize > 80% circulating viral variants)14. During natural 
infection, HIV evades the neutralization pressure exerted 
by the patient´s broadly neutralizing antibodies; however, 
the passive administration of broadly neutralizing mono-
clonal antibodies (bnMAbs) can modulate HIV viremia. 
In the last decade, several technological advancements 
allowed the recovery of a large group of bnMAbs targeting 
different epitopes on HIV envelope protein (Env)15; the 
efficacy of some of these antibodies preventing and con-
trolling HIV infection have already been tested in different 
preclinical and clinical settings.
Preclinical testing of bnMAbs in animal models of 
HIV infection
To date, several studies showed that, when administered in 
advance of virus challenge,  the passive infusion of bnMAbs 
was able to block HIV or SHIV (simian-human immunode-
ficiency virus) infection in mouse and macaque models of 
HIV infection, respectively16. These results indicate that a 
vaccine able to elicit a similar humoral immune response 
in humans would effectively prevent HIV infection. 
Another series of studies showed that the passive 
administration of different combinations of bnMAbs to 
macaques chronically infected with SHIV was effective in 
suppressing viremia and avoiding the emergence of re-
sistant viral variants17. Remarkably, if administered during 
the first 24 hs after infection the combination of bnMAbs 
interfered with the establishment of the viral reservoir and 
allowed a complete clearance of the virus18. 
Importantly, preclinical trials have shown that the ef-
fect of bnMAbs exceeds its ability to neutralize free viral 
particles; in addition, bnMAbs can induce the killing of 
HIV-infected cells through the engagement of Fc-recep-
tor (Fc-R) present in NK and phagocytes19, 20. Moreover, 
bnMAbs can control excessive virus replication, induce 
the formation of immune complexes, and exert an strong 
selective pressure on Env; altogether these features can 
boost the immune response against HIV21, 22. 
Of note, since bnMAbs have a particular biodistribution, 
they could reach different body compartments where ART 
do not penetrate, as is the case of the germinal centres 
in the lymph nodes.  
Long-lasting HIV suppression by combined 
immunotherapy 
To date, two bnMAbs directed to the CD4-binding site 
(VRC01 and 3BNC17) and one bnMAb targeting a glycan 
site present in the third hyper variable loop (V3) on Env 
have been separately used in a series of clinical trials. In 
general, monotherapy with these powerful bnMAbs was 
safe and showed a modest effect in reducing viremia and 
delaying viral rebound in HIV-chronically infected people 
who were not receiving ART and those who were under 
analytical treatment interruption (ATI), respectively23-27. 
Treatment effectiveness (i.e. viremia reduction and time 
to rebound) was associated with the neutralization sensi-
tivity of the different viral variants present at the initiation 
of treatment. However, single bnMAb therapy did not 
maintain long-term HIV suppression and resistant viral 
variants arose. Since no single bnMAb is able to neutral-
ize all circulating HIV variants with sufficient potency, it 
is necessary to combine at least two bnMAbs, targeting 
different Env sites in order to increase immunotherapy 
efficacy and avoid the emergence of resistance. In this 
regard, two recent studies have shown that combined 
immunotherapy with 3BNC117 and 10-1074 induced 
long-lasting viremia control in people chronically infected 
with HIV28, 29.
Challenges associated with the use of bnMAbs in 
clinical settings 
Apart from the emergence and selection of resistant viral 
variants, several challenges associated with the use of 
bnMAbs must be considered, as is the case of the high 
cost of bnMAb production, the frequency and route of 
administration, and bnMAbs biodistribution in vivo. These 
limitations prompted the rational design of different bio-
engineered bnMAbs with greater neutralization breadth, 
higher potency, enhanced Fc-function and extended 
half-life. As an alternative to combined immunotherapy, 
multivalent bnMAbs (targeting several vulnerability sites 
on Env) have been developed. Xu and col. developed 
a tri-specific-bnMAb with the highest potency and neu-
tralization breadth (> 99% of 208 tested viral variants) 
for a single molecule described to date30. Moreover, the 
addition of particular point-mutations into the Fc region 
of the VRC01-LS molecule can increase the antibody 
binding to the neonatal Fc-R, leading to extended in vivo 
half-life. Based on preliminary data, it has been estimated 
that the VRC01-LS version of VRC01 could maintain its 
therapeutic effect if administered subcutaneously twice a 
year31. Further modifications in the Fc region of bnMAbs 
can enhance the antibody effector function, and con-
sequently, increase the clearance of HIV-infected cells 
induced by bnMAbs32. Such antibodies might account 
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for a stronger reduction of the viral reservoir, potentially 
allowing a functional cure of HIV infection. Although most 
of these novel modified-bnMAbs remain yet to be tested in 
clinical settings, there is general agreement in that these 
upgrades will allow to reduce the number of doses and 
dosages, and most importantly, the treatment cost.
Prophylactic effect of bnMAbs
Currently, two large scale phase 2b clinical trials –enrolling 
4200 participants– have been initiated to test the efficacy 
of VRC01 in preventing HIV acquisition in high risk popula-
tions33. If effective, these studies will also define protective 
antibody titres and other correlates of protection, which 
in turn will help to evaluate future vaccine candidates. In 
addition, a series of studies are evaluating the safety and 
efficacy of VRC01 for the prevention of mother-to-child 
transmission of HIV.
Therapeutic vaccines
Therapeutic HIV vaccines aim to improve the im-
mune response of HIV-infected persons in order to 
modulate the clinical progression of the disease and 
avoid the evolution of AIDS. Additionally, treating 
people with these vaccines would ideally keep HIV at 
undetectable levels without the need for daily ART. 
In the previous sections we explained how long-
acting ART and bnMAbs with increased half-lives 
could contribute to this strategy. Other approaches 
include vector-mediated gene transfer to secrete 
bnMAbs into circulation (vectored immunoprophy-
laxis or VIP), the ex vivo stimulation of T-cells, 
and the use of cytokines to re-direct and potentiate 
the immune response. Another strategy known as 
shock-and-kill consists of a two-step process where 
latency-reversing agents induce HIV transcriptional 
reactivation in latently infected cells, and then, re-
activated cells can be efficiently eliminated by the 
immune system or anti-HIV drugs. By targeting the 
latent viral reservoir, this approach could potentially 
eliminate HIV from the body thus achieving the 
functional cure of HIV infection. Although there is 
currently a large number of therapeutic HIV vaccines 
under development and evaluation, none of them is 
approved for use in patients.
Final considerations
The history of ART has shown unprecedented advances 
in the field of medicine. Only 6 years elapsed between 
the description of the first AIDS cases (1981) and the ap-
proval of the first drug with proven antiretroviral activity, 
zidovudine (1987); today we have 32. Current formula-
tions allow prescribing combination therapy of 2 or 3 
drugs with only 1 or 2 tablets, taken daily. The efficacy 
of current regimens, especially those based on integrase 
inhibitors, exceeds 90%, with excellent tolerance and 
easier adherence to treatment. Despite the lack of an 
effective vaccine, the global increase in ART coverage 
has reduced the numbers of AIDS-associated deaths 
and new infections.
While ART suppresses viral load effectively, HIV re-
bounds rapidly once treatment is interrupted, even after 
years of viral suppression. For this reason, the possibility 
of combining ART with other therapies directed against 
the viral reservoir has gained interest. About ten years 
ago, a case of HIV cure has been reported in a patient 
undergoing stem cell therapy (a second case with similar 
characteristics still needs to be confirmed)34. However, 
the complexity and risks associated with this kind of 
interventions prevent their generalization. On the other 
hand, bnMAbs could complement ART due to their ability 
to neutralize free viral particles, enhance the immune re-
sponse and induce the destruction of HIV-infected cells. 
The first clinical trials with bnMAbs have demonstrated 
that combination immunotherapy can contain viral loads 
for prolonged periods without the emergence of resist-
ance. The current challenge is to optimize all available 
resources to design better therapeutic and prophylactic 
regimens until an effective vaccine against all circulating 
HIV variants is developed.
The future of this epidemic depends on the political 
will of governments to meet the goals of UNAIDS, 
which means diagnosing 90% of people living with the 
virus, treating 90% of those diagnosed, and maintain-
ing undetectable viral load in 90% of those treated. 
This strategy of “treatment as prevention”, associated 
with the expansion of PrEP, could allow to control the 
epidemic in little more than a decade. No infectious 
disease has been eradicated in the absence of an 
effective preventive vaccine and/or a cure strategy. 
On the way to both objectives, a comprehensive 
approach would combine the excellence of available 
antiretroviral drugs with strategies to enhance immune 
system activity (e.g., immunotherapy with bnMAbs or 
a therapeutic vaccine). If we apply such an approach 
in a social context free of stigma and discrimination, 
we can look to the future with cautious, but renewed, 
optimism.
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